H2020Индивидуална стипендия2017–2020

IMMUNO_CRC · Microbiota-immune interaction in colorectal cancer

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2017-04-01 → 2020-07-31
Финансиране от ЕС: 187 866 €
Участници: 1
Схема: MSCA-IF-EF-RI

Линиите свързват координатора с партньорите.

Накратко на български

Връзката между бактериите в червата и имунната система при рак на дебелото черво се анализира чрез миша модели и генетични тестове. Разбирането на тези процеси помага за разработването на нови методи за подобряване на състоянието на пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Microbiota-immune interaction in colorectal cancer

Colorectal cancer (CRC) is one of the most common cancers in humans, with nearly 1.4 million new cases diagnosed globally in 2012. In Ireland, CRC is the third leading cause of death in women and the second cancer-mortality in men (National Cancer Registry 2019). Given the high morbidity and mortality from this disease, it is vital to develop new strategies and ways of thinking to improve the patients’ outcomes. Significant risk factors for CRC include diets rich in fat and red meat, obesity, and chronic inflammation of the gastrointestinal tract, all of which are closely associated with changes in the gut microbiota. The gut microbiota is the community of trillions of microbes living in the intestine, which play an essential role in our health. An altered gut microbiota has been associated with CRC and previous studies have established an important role for some gut microbiota members in cancer progression, outcome and response to therapy. Therefore, strategies aimed at manipulating the tumour-associated gut microbiota in CRC represent a promising therapeutic approach for patients. The overall goal of the IMMUNO-CRC project was to understand how certain gut microbiota groups, identified in CRC patients may alter the immune response and influence clinical outcome. To achieve this goal, we used a combination of advanced techniques, including microbiome sequencing, gene transcriptomics, histology and multi-colour flow cytometry. Also, we transferred human-associated microbial populations from patients with CRC into a well-established mouse model of human CRC, ensuring, therefore, a direct translational potential for human medicine. A parallel goal of the IMMUNO-CRC project was to foster the career development of the researcher.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The human gastrointestinal tract harbours trillions of bacteria that have co-evolved to play important roles in health and disease, conferring immunological, metabolic and neurological benefits to the host. This assemblage is known as the Gut Microbiota and has been a focus of investigation over the last decade. Altered gut microbiota composition has been associated with colorectal cancer (CRC), and studies in germ-free mice established an important role for some gut microbiota members in oncogenesis outcome, tumour progression and response to therapy. Data from the host laboratory show that patients with CRC harbour specific gut microbiota sub-types, among which some are associated with distinct mucosal gene-expression profiles. Thus either directly or through their metabolites, these tumour-associated microbiota appear to differentially recruit and interact with host inflammatory cells, which we hypothesize may be involved in different outcomes of carcinogenesis. The presence of particular immune cells is known to be prognostic of clinical outcome, because it often creates a tumour-promoting environment. Therefore, strategies aimed at manipulating the tumour-associated microbiota in CRC represent a promising therapeutic approach for patients. IMMUNO-CRC’s goal is to elucidate the mechanisms by which certain bacterial sub-types associated with CRC may alter immune function and influence clinical outcome. Using multicolour flow cytometry, I will analyse infiltrating immune cells characteristic of different inflammatory responses and microbiota sub-types. Histo-immunophenotyping analysis on tumour biopsies will determine their inflammation and cancer phenotype. Metabolomics will identify specific microbial metabolites involved in the regulation and progression of inflammation. Ultimately, this unique and innovative combination of techniques will pave the way for novel therapeutics targeting the human microbiota for cancer treatment.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK · CorkКоординаторИрландия